
|Articles|November 1, 2012
Botulinum toxin with unique makeup compares to market leader
As the popularity of botulinum toxins for both cosmetic and therapeutic applications continues to grow, so too does development of new techniques and formulations. IncobotulinumtoxinA (Xeomin, Merz), the newest of the toxin formulations, is a promising product that according to clinical studies exhibits similar efficacy to onabotulinumtoxinA (Botox, Allergan), despite having a distinctly different biological makeup.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
2
Kyowa Kirin Takes Full Control of Rocatinlimab Program
3
FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA
4
Dermatology Times January 2026 Recap
5











